US patent for Neuropilin-1 receptor (9960W)
February 08 2012 - 2:00AM
UK Regulatory
TIDMAKT
RNS Number : 9960W
Ark Therapeutics Group PLC
08 February 2012
ARK THERAPEUTICS GROUP PLC
Notice of Allowance of US patent for Neuropilin-1 receptor
("NRP-1") small molecule antagonists
London - 8 February 2012, London, UK: Ark Therapeutics Group plc
("Ark" or the "Company") announces that the United States Patent
and Trademark Office ("USPTO") has issued a Notice of Allowance in
respect of a patent covering the structures of candidate compounds
in Ark's Neuropilin-1 receptor ("NRP-1") small molecule antagonist
programme. Formal grant of this patent is expected in two
months.
Ark has developed the first drug-like small molecule antagonists
of VEGF binding to NRP-1 which, in pre-clinical in vivo studies,
show inhibition of both tumour growth and the development of the
tumour blood supply (anti-angiogenic) as well as directly impairing
tumour cell growth and migration. The novel chemistry is supported
by structure-aided design utilizing x-ray crystallography. These
efforts are continuing to optimize the compounds directed towards
this emerging target for therapeutic exploitation.
Martyn Williams, Chief Executive of Ark commented: "We are
pleased to report the further strengthening of the patent
protection that Ark's unique NRP-1 antagonist programmes enjoys.
Partnering discussions for further development of this programme
continue with companies that wish to boost their early development
oncology pipelines."
John Martin, Chief Scientific Officer of Ark commented: "This
exciting programme will hopefully generate an entirely new class of
small molecule anti-cancer therapeutics with activity across all
solid tumours and in so doing provide cancer sufferers with a
powerful new weapon against this terrible disease."
For further information please contact:
Ark Therapeutics Group plc Tel: + 44 (0)20 7388 7722
Martyn Williams, CEO
Iain Ross, Chairman
FTI Consulting Tel: +44 (0)20 7831 3113
Ben Atwell
Susan Quigley
Ark Therapeutics Group plc
Ark Therapeutics Group plc is a specialist healthcare group (the
"Group") addressing high value areas of unmet medical need within
vascular disease and cancer. These are large and growing markets,
where opportunities exist for effective new products to generate
significant revenues.
Ark has an early stage pipeline emanating from collaborations
with University College, London and the AI Virtanen Institute in
Kuopio, Finland, the development of which it intends to progress in
collaboration with pharmaceutical and biotech partners.
In addition Ark has the ability to off-set a proportion of its
R&D costs and to generate sustainable revenues through the
exploitation of its proprietary technology platform, process
development, scale-up and manufacturing capabilities on behalf of
third parties.
Ark has its origins in businesses established in the mid-1990s
by Professor John Martin and Mr Stephen Barker of University
College London and Professor Seppo Yla-Herttuala of the AI Virtanen
Institute at the University of Kuopio, Finland, all of whom remain
consultants on the Company's research and development
programmes.
Ark's shares were first listed on the London Stock Exchange in
March 2004 (AKT.L).
This announcement includes "forward-looking statements" which
include all statements other than statements of historical facts,
including, without limitation, those regarding the Group's
financial position, business strategy, plans and objectives of
management for future operations (including development plans and
objectives relating to the Group's products and services), and any
statements preceded by, followed by or that include forward-looking
terminology such as the words "targets", "believes", "estimates",
"expects", "aims", "intends", "will", "can", "may", "anticipates",
"would", "should", "could" or similar expressions or the negative
thereof. Such forward-looking statements involve known and unknown
risks, uncertainties and other important factors beyond the Group's
control that could cause the actual results, performance or
achievements of the Group to be materially different from future
results, performance or achievements expressed or implied by such
forward-looking statements. Such forward-looking statements are
based on numerous assumptions regarding the Group's present and
future business strategies and the environment in which the Group
will operate in the future. Among the important factors that could
cause the Group's actual results, performance or achievements to
differ materially from those in forward-looking statements include
those relating to Ark's funding requirements, regulatory approvals,
clinical trials, reliance on third parties, intellectual property,
key personnel and other factors. These forward-looking statements
speak only as at the date of this announcement. The Group expressly
disclaims any obligation or undertaking to disseminate any updates
or revisions to any forward-looking statements contained in this
announcement to reflect any change in the Group's expectations with
regard thereto or any change in events, conditions or circumstances
on which any such statements are based. As a result of these
factors, readers are cautioned not to rely on any forward-looking
statement.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLDLLBLLFFBBV
Premier Veterinary (LSE:PVG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Premier Veterinary (LSE:PVG)
Historical Stock Chart
From Jul 2023 to Jul 2024